A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs ABBV 176 (Primary)
- Indications Adrenocortical carcinoma; Advanced breast cancer; Colorectal cancer; Liver cancer; Male breast cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
- 10 Jun 2020 Results published in the Investigational New Drugs
- 28 Nov 2018 Status changed from suspended to discontinued.
- 28 Aug 2018 Status changed from recruiting to suspended due to safety issues.